Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Déjà Vu: Boston Scientific’s Emblem Racks Up Another Class I Recall This Month

Executive Summary

The US FDA on 19 February designated a recall of the Emblem S-ICD Subcutaneous Implantable Cardioverter Defibrillator as high-risk class I. The recall comes on the heels of a second, separate class I recall for the Emblem electrode on 2 February.

You may also be interested in...



Safety Mode Troubles Lead To Class I Recall For Boston Scientific’s Ingenio Pacemakers

The device giant recalled its Ingenio family of pacemakers and cardiac resynchronization therapy pacemakers (CRT-Ps) because there’s a chance they can slip into safety mode, posing a risk to patients. It’s Boston Scientific’s fifth high-risk class I this year.

Boston Scientific’s Vici Stent Systems Subject Of Class I Recall

The company pulled the products from shelves because there’s a chance the stents can migrate, or move, from where they’re placed. This is Boston Scientific’s fourth high-risk class I recall this year.

Death, Serious Injuries Lead To Class I Recall For Boston Scientific’s Emblem Electrode

The US FDA affixed its highest-risk classification to a recall of the electrode, which is part of the company’s Emblem S-ICD system.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel